The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Mon., Jul. 22, 8:29 AM

Slide #4. Xenetic Biosciences, Inc. (NASDAQ:XBIO) 1 for 12 Reverse Split

Announced: 6/24/2019
Stock Split: 1 for 12
Record Date: 6/24/2019
Pay Date: 6/25/2019
XBIO Optionable?: No

Xenetic Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, research and development of biologic drugs and oncology therapeutics. Co.'s lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin - resistant endometrial cancer. Co.'s second internal drug candidate is ErepoXen, or polysialylated erythropoietin (PSA-EPO), which uses Co.'s PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. Co.'s drug candidate OncoHist, which has clinical proof of concept, utilizes the properties of modified human histone H1.3 for targeted cell killing.
XBIO Detailed Information Page & Split History »

Company Name: 
Xenetic Biosciences Inc
Drugs & Pharmaceuticals

Open the XBIO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Stock Splits Page |

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.